Disease modification in Parkinson's disease (Q44713421)

5 December 2017

1 reference

title

Disease modification in Parkinson's disease (English)

1 reference

5 December 2017

1 reference

Claire Henchcliffe

1

1 reference

PubMed ID

21812497

5 December 2017

W Lawrence Severt

series ordinal

2

1 reference

5 December 2017

1 August 2011

1 reference

5 December 2017

1 reference

5 December 2017

28

1 reference

5 December 2017

8

1 reference

5 December 2017

605-615

1 reference

https://scigraph.springernature.com/pub.10.2165/11591320-000000000-00000

5 December 2017

0 references

cites work

Levodopa and the progression of Parkinson's disease

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Neuroprotection trials in Parkinson's disease: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Dietary intake of antioxidant vitamins and risk of Parkinson's disease: a case-control study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Neuroprotection of pramipexole in UPS impairment induced animal model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Neuroprotection and imaging studies in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

The delayed-start study design.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Calcium, ageing, and neuronal vulnerability in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Plasma urate and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Urate as a predictor of the rate of clinical decline in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Treatment of Parkinson's disease with trophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Parkinson disease: Another player in gene therapy for Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

The delayed-start study in Parkinson disease: can't satisfy everyone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11591320-000000000-00000

The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo

21 January 2018

1 reference

12 December 2020

Neuroprotection by (R)-deprenyl and 7-nitroindazole in the MPTP C57BL/6 mouse model of neurotoxicity

1 reference

12 December 2020

Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study

1 reference

12 December 2020

1 reference

12 December 2020

In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.

1 reference

12 December 2020

Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat

1 reference

12 December 2020

Minimal clinically important change on the unified Parkinson's disease rating scale

1 reference

12 December 2020

Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.

1 reference

12 December 2020

10.2165/11591320-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

21812497

Dimensions Publication ID

5 December 2017

0 references

1 reference

PubMed ID

21812497